Journal article
CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action
- Abstract:
-
CD6 is a type I T cell surface receptor which modulates antigen receptor signalling. Its activity is regulated by binding of its membrane proximal domain (domain 3) to a cell surface ligand, CD166. CD6 monoclonal antibodies (mAbs) specific for the membrane distal domain (domain 1) perturb CD6 function including itolizumab (Alzumab™) which has reached the clinic for treatment of autoimmune disease. We characterised molecular and functional properties of several CD6 mAbs including itolizumab to...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted Manuscript
Actions
Access Document
- Files:
-
-
(pdf, 1.5MB)
-
- Publisher copy:
- 10.1111/imm.12952
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
Bibliographic Details
- Publisher:
- John Wiley & Sons Ltd Publisher's website
- Journal:
- Immunology Journal website
- Volume:
- 155
- Issue:
- 2
- Pages:
- 273-282
- Publication date:
- 2018-06-13
- Acceptance date:
- 2018-05-11
- DOI:
- EISSN:
-
1365-2567
- ISSN:
-
0019-2805
- Pubs id:
-
pubs:852265
- URN:
-
uri:cb871e93-af75-44af-8331-ebad49db76e0
- UUID:
-
uuid:cb871e93-af75-44af-8331-ebad49db76e0
- Local pid:
- pubs:852265
Item Description
Terms of use
- Copyright holder:
- John Wiley & Sons Ltd
- Copyright date:
- 2018
- Notes:
-
Copyright © 2018 John Wiley & Sons Ltd. This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1111/imm.12952
If you are the owner of this record, you can report an update to it here: Report update to this record